In 2012, an all-time high of 28,000 principal investigators participated in FDA regulated research, according to a study in the March/April Tufts Center for the Study of Drug Development (CSDD) Impact Report. However, compound annual growth in the number of active...
The Clinical Trials Transformation Initiative (CTTI), a public-private organization created to improve the way clinical trials are conducted, established the Patient Leadership Council (PLC) to involve patient advocates in its objective. The 16 member council composed...
The Tufts Center for the Study of Drug Development (TCSD) has released data showing that between 2004 and 2012 the number of endpoints per protocol has increased from an average of eight per protocol in the earlier period to 14 endpoints in the later period. To read...
The healthcare industry, medical research and drug approval process are projected to be greatly affected by the federal budget cuts scheduled for March 1, according to a recent article on mondernhealthcare.com. The Budget Control Act of 2011, originally scheduled to...
Join Pearl staff and clinical research professionals at the MAGI Clinical Research Conference in Boston, May 5-8, 2013. Pearl’s Gretchen Bowker will be presenting “Medical Device Regulations: How device and drug regulations and guidances differ” during the Regulatory...
Numerous pharmaceuticals are approved and marketed based on the premise that they favorably change disease state-biomarkers. However, recent data has shown that altering the biomarkers indicative of disease does not necessarily translate to ameliorated health. In an...
